HWHaikun Wang

Haikun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haikun Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Caiying Wang

    Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Duanfang Cao

    National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

    1 shared publication
  • Haikun Wang

    State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

    1 shared publication
  • Hong Fan

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Huichun Shi

    Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China

    1 shared publication
  • Jiahao Jiang

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis

    by Yongqiang Ao, Jian Gao, Zhen Ying, Shuai Wang, Zheng Han, Mingyu Xia, Jiazhe Wen, Junkan Zhu, Caiying Wang, Minjie Fu, et al.

    The pathogenic mechanisms through which thymoma induces myasthenia gravis (MG) remain incompletely understood. While MG pathogenesis involves neuromuscular


  • Open Access

    A Bivalent mRNA Vaccine Efficiently Prevents Gammaherpesvirus Latent Infection

    by Yannan Yin, Jinkai Zang, Huichun Shi, Zhuang Wang, Linlin Kuang, Shuxia Wang, Haikun Wang, Ning Li, Xiaozhen Liang, Zhong Huang

    Background: It is still challenging to develop effective vaccines against tumorigenic human gammaherpesviruses such as Epstein–Barr virus (EBV). A major obstacle is the lack of a small animal model that reproduces the natural infection course of human gammaherpesviruses to allow for proper assessment of vaccine efficacy. Murine gammaherpesvirus 68 (MHV68) is a natural pathogen of wild rodents and laboratory mice and therefore can be used as a surrogate for human gammaherpesviruses to evaluate vaccination strategies. Methods: In this study, two mRNA vaccine candidates were generated, one encoding a fusion protein of the MHV68 gH with the gL (gHgL-mRNA) and the other expressing the MHV68 gB protein (gB-mRNA). The immunogenicity and protective efficacy of the mRNA vaccine candidates were evaluated in a mouse model of MHV68 infection. Results: The gHgL-mRNA but not the gB-mRNA candidate vaccine was able to induce neutralizing antibodies in mice, whereas both vaccines could elicit antigen-specific T-cell responses. Following MHV68 intranasal inoculation, complete blocking of the establishment of viral latency was observed in some mice immunized with individual gHgL-mRNA or gB-mRNA vaccines. Notably, co-immunization with the two mRNA vaccines appeared to be more effective than individual vaccines, achieving sterile immunity in 50% of the vaccinated mice. Conclusions: This study demonstrates that immunization with mRNA platform-based subunit vaccines is indeed capable of preventing MHV68 latent infection, thus validating a safe and efficacious vaccination strategy that may be applicable to human gammaherpesviruses.


  • Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2

    by Kai Wang, Duanfang Cao, Lanlan Liu, Xiaoyi Fan, Yihuan Lin, Wenting He, Yunze Zhai, Pingyong Xu, Xiyun Yan, Haikun Wang, et al.

    Neutralizing antibodies have been designed to specifically target and bind to the receptor binding domain (RBD) of spike (S) protein to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from attaching to angiotensin converting enzyme 2 (ACE2). This study reports a distinctive nanobody, designated as VHH21, that directly catalyzes the S-trimer into an irreversible transition state through postfusion conformational changes. Derived from camels immunized with multiple antigens, a set of nanobodies with high affinity for the S1 protein displays abilities to neutralize pseudovirion infections with a broad resistance to variants of concern of SARS-CoV-2, including SARS-CoV and BatRaTG13. Importantly, a super-resolution screening and analysis platform based on visual fluorescence probes was designed and applied to monitor single proteins and protein subunits. A spontaneously occurring dimeric form of VHH21 was obtained to rapidly destroy the S-trimer. Structural analysis via cryogenic electron microscopy revealed that VHH21 targets specific conserved epitopes on the S protein, distinct from the ACE2 binding site on the RBD, which destabilizes the fusion process. This research highlights the potential of VHH21 as an abzyme-like nanobody (nanoabzyme) possessing broad-spectrum binding capabilities and highly effective anti-viral properties and offers a promising strategy for combating coronavirus outbreaks.